"With new and reinvigorated marketing partners, as well as fresh products and market opportunities, GeneLink believes 2013 offers new opportunities for growth in the consumer rapidly maturing genomics marketplace."Dr. Kasten added, "In a development which should not be overlooked, GeneLink completed over 18 months of cooperation with the Federal Trade Commission (the "Commission") when it entered into a proposed Consent Agreement with the staff of the Commission. The tentative agreement, which awaits final approval by the Commissioners, does not provide for any financial obligations by the Company and provides us with useful guidance moving forward. To the best of our knowledge, GeneLink is the first consumer genetics company to negotiate such an agreement, a testament to the strength of our Scientific Advisory Board and the integrity of our approach."
GeneLink Reports 2012 Financial Results
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.